Drug

Zaynich receives CDSCO approval ahead of FDA nod

Zaynich is a newly approved broad‐spectrum antibiotic indicated for multi-drug resistant bacterial infections, including refractory odontogenic infections. Standard adult dosing is 500 mg orally twice daily. The Central Drugs Standard Control Organization granted approval on May 27, 2026, and Wockhardt has also secured FDA clearance, with marketing initiated in India. Clinically relevant for dentists managing complicated oral infections.

Source: Biotecnika

Read more dental news on DentalSync

22 Nov 2026 · DentalSync AI — global BDS career platform